December 12, 2014 In a momentous decision that would have wide-ranging implication for access to medicines, the Supreme Court of India refused to entertain Bayer’s appeal to set aside the compulsory license (CL) on Sorafenib (Nexavar). The Supreme Court’s dismissal of Bayer’s Special Leave Petition against the Bombay High Court’s decision upholding of the CL…

10 September, 2014- In a move towards furthering access to affordable medicines, Lawyers Collective through Sankalp Rehabilitation Trust, the Hepatitis Coalition of Nagaland and Network of PLHIV living in the Asia Pacific region (APN+), filed a pre- grant challenge to sofosbuvir (Sovaldi) in India. The opposition is against the pro-drug patent application 3658/kolnp/2009 which is…

15.07.2014- In a momentous decision for patients, a Division Bench of the Bombay High Court dismissed a writ petition filed by Bayer challenging the IPAB order upholding the compulsory license granted to Natco for Sorafenib Tosylate (Nexavar). Nexavar is a crucial medicine for patients suffering from kidney and liver cancer. In 2012, the Patent Controller…

March 27, 2014 Dr. Manmohan Singh Hon’ble Prime Minister of India, The Prime Minister’s Office, South Block, Raisina Hill, New Delhi 110011. Tel: 011 23018939; Fax: 011 2301 0233. Email: manmohan@sansad.nic.in Resist the US administration Pressure and Reject the Misleading Allegations of US Business Associations  We the undersigned organizations and individuals are writing this letter…

31st March, 2014: The Naz Foundation (India) Trust, the original petitioner in the constitutional challenge to Section 377, has filed a curative petition challenging the Supreme Court decision in Suresh Kumar Koushal v. Naz Foundation (hereinafter ‘Koushal’) delivered in December, 2013 that upheld the validity of Section 377, IPC and set aside the Delhi High…

30th January, 2014: The Intellectual Property Appellate Board (IPAB) set aside the Patent Controller’s decision to revoke the patent relating to valganciclovir on technical grounds and remanded it to the Controller for re-consideration. In a significant development for patient groups, the IPAB rejected the demand of the patentee, Hoffman La Roche, to restore the patent…

IT has been more than a year since the first compulsory licence was granted to an Indian company manufacturing generic drugs to produce a patented drug. In March 2012, the compulsory licence granted to Natco for manufacturing sorafenib tosylate (brand name Nexavar), a drug whose patent was owned by the pharma giant Bayer Corporation, had significant implications…

Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a hearing, ‘A tangle of trade barriers’ before the US Energy and Commerce Committee saw witness testimonies including that…

2014 © Copyright - Lawyers Collective Designed by CGD